Here are the Efficacy and safety of semaglutide: real-world tertiary care experience from Saudi Arabia journals presenting the latest research across various disciplines. From social sciences to technology, each article is expected to provide valuable insights to our readers.
Efficacy and efficiency difference, hoodia research on safety and efficacy, efficacy and safety of umbilical, efficacy and effectiveness difference, semaglutide 1 mg effectiveness, efficacy and safety of ritlecitinib, efficacy and safety of umbilical, how safe is semaglutide infosemaglutide, semaglutide for human use.
Efficacy and safety of semaglutide: real-world tertiary care experience from Saudi Arabia
BACKGROUND: Semaglutide, a glucagon-like peptide-1, is an effective antidiabetic drug promoting weight loss and providing cardiovascular protection. The original trials did not include participants from Saudi Arabia; hence, the study's findings are expected to be useful. OBJECTIVES: Explore the efficacy, safety, and favorable effects of once-weekly subcutaneous semaglutide (1 mg) in patients with type 2 diabetes and those who received it as an off-license prescription without having diabetes. DESIGN: Retrospective review of medical records. SETTING: Department of medicine at our institution. PATIENTS AND
METHODS: This retrospective observational study evaluated patients receiving the glucagon-like peptide-1 analog semaglutide, with the trade name Ozempic. The weight, height, body mass index, blood pressure, and laboratory data, including serum creatinine and hemoglobin A1c (HbA1c) levels and urine albumin/creatinine ratio, were recorded. Moreover, any history of medical comorbidities, such as cardiovascular diseases, cerebrovascular diseases, and heart failure, was documented before and after drug administration. MAIN OUTCOME MEASURES: Glycemic and weight loss efficacy. SAMPLE SIZE: 1007 patients.
RESULTS: The median age of the patients was 57.0 years, comprising 60.28% females. Among them, 955 and 442 patients received the medication for at least 3 and 6 months, respectively. Our results show a 4.4% weight loss and 0.4% improvement in HBA1c in patients with diabetes. Similar results were observed in the patients without diabetes in terms of weight along with a significant decrease in diastolic blood pressure. Our results also show stability in the serum creatinine and urine albumin creatinine ratio. The drug was equally effective in males and females.
CONCLUSION: Treatment with once-weekly subcutaneous semaglutide (1 mg) led to clinically significant weight loss and improved HbA1c level and cardiometabolic risk factors such as blood pressure. LIMITATIONS: Retrospective design.
Authors : Butt M.I.; Alkhalifah K.M.; Riazuddin M.; Almuammar S.M.; Almuammar S.M.; Alhifthi G.A.; Ahmed F.W.; Al Hashim S.M.; Waheed N.
Source :
Article Information
| Year | 2024 |
| Type | Article |
| DOI | 10.5144/0256-4947.2024.361 |
| ISSN | 09754466 |
| Volume | 44 |
You can download the article here
If You have any problem, contact us here